1000815-27-9

Basic information

• Product Name: 8-BroMo-5-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester
• Synonyms: 8-BroMo-5-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester;ethyl 8-bromo-5-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
• CAS NO: 1000815-27-9
• Molecular Formula: C₁₂H₉BrFNO₃
• Molecular Weight: 314.1071632
• Mol File: 1000815-27-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-BroMo-5-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BroMo-5-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester(1000815-27-9)
• EPA Substance Registry System: 8-BroMo-5-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester(1000815-27-9)

Safety Data

• Hazardous Substances Data: 1000815-27-9(Hazardous Substances Data)

Upstream product

• 364-78-3 2-nitro-4-fluoroaniline 
• 1003-99-2 2-bromo-5-fluoroaniline 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 655236-27-4 diethyl {[(2-bromo-5-fluorophenyl)amino]methylene}malonate 
• 446-09-3 2-bromo-5-fluoronitrobenzene 

Relevant articles and documents

High affinity central benzodiazepine receptor ligands. Part 3: Insights into the pharmacophore and pattern recognition study of intrinsic activities of pyrazolo[4,3-c]quinolin-3-ones

Novel 2-phenyl-2,5-dihydropyrazolo[4,3-c]quinolin-3-(3H)-ones (PQs) endowed with high affinity for central benzodiazepine receptor (BzR) were synthesized. In particular, 9-fluoro-2-(2-fluorophenyl)-2,5-dihydro-3H- pyrazolo[4,3-c]quinolin-3-one (22) showed binding affinity in the subnanomolar concentration range and proved to be in vitro a potent antagonist. This finding allowed the nature of the hydrogen bonding receptor site H 2 to be established, as located between the N-1 nitrogen of the PQ nucleus and the ortho position of the N-2-aryl group. [35S]tert- Butylbicyclophosphorothionate ([35S]TBPS) binding assays and electrophysiological measurements of the effects on GABA-evoked Cl- currents at recombinant human α1β2γ 2L GABAA receptors, expressed in Xenopus laevis oocytes, were used to assess the intrinsic activities of a large series of PQs. With the aim of extracting discriminant information and distinguishing BzR ligands with different profiles of efficacy, 51 PQ derivatives, including full and partial agonists, antagonists, and inverse agonists, were analyzed in a multidimensional chemical descriptor space, defined by the lipophilicity parameter CLOG P and 3-D molecular WHIM descriptors, by means of principal component analysis, k-nearest neighbors (k-NN) method, and linear discriminant analysis (LDA). The classification methods were applied to subsets of pairs of efficacy classes, and lipophilicity and 3-D size descriptors were detected as the discriminant variables by a stepwise linear discriminant analysis. LDA proved to be superior to k-NN, especially in classifying PQ ligands (60-84% of success in prediction ability) into categories of efficacies which were contiguous and quite overlapped in the hyperspace of variables.

BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to benzyl-substituted quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheime